Two episodes of ifosfamide-related neurotoxicity in the same patient following different schedules and doses of the drug. A case report.
We report the first case of recurrent ifosfamide-related neurotoxicity in the same patient following two distinct administrations of the drug at different doses and schedules and with a long interval between the two episodes. Remarkably, the first event was characterized by confusion and hallucinations, while the second, 29 months later, was characterized by partial and generalized seizures. Between the two episodes the patient had received high-dose cyclophosphamide, an oxazophoshorine agent closely related to ifosfamide, without any neurological side effects. We briefly discuss the diagnosis and management of ifosfamide-related encephalopathy.
Comandone
A
A
Medical Oncology Department, Ospedale Gradenigo, Turin, Italy. sandro56@sirio-oncology.it
Liboni
W
W
Picci
P
P
Oliva
C
C
Pignatta
P
P
Dal Canton
O
O
Bergnolo
P
P
Cutin
S C
SC
Boglione
A
A
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D006212:Hallucinations / Q000139:chemically induced*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008297:Male; D020360:Neoadjuvant Therapy; D012516:Osteosarcoma / Q000188:drug therapy; D012640:Seizures / Q000139:chemically induced*; D013977:Tibia
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide